Heroin Dependence: Clinical Trials

19 trials for Heroin Dependence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 3 unknown, 1 terminated, 1 withdrawn. 19 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 319Completed 14, Unknown 3, Terminated 1, Withdrawn 1
Phase 25Completed 4, Withdrawn 1

Follow Heroin Dependence: new trials by email Literature Review of Heroin Dependence trials Research Report on Heroin Dependence

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
Buprenorphine/naloxone - Heroin Dependence
Phase 3TerminatedNew York State Psychiatric Institute82018-11-012022-12-22
Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
Mirtazapine, Placebo - Heroin Dependence, Amphetamine Dependence
Phase 3UnknownUniversiti Sains Malaysia802013-05-012015-09-04
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
paliparidone - Heroin Dependence, Amphetamine Dependence
Phase 3UnknownUniversiti Sains Malaysia402013-05-012015-09-04
An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
Minocycline - Heroin Dependence, Amphetamine Dependence
Phase 3UnknownUniversiti Sains Malaysia402013-04-012015-09-04
Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)
Hydromorphone, Injectable, Diacetylmorphine, injectable, Hydromorphone, liquid oral - Opioid Dependence, Heroin Dependence
Phase 3CompletedUniversity of British Columbia2022011-12-012016-06-07
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
Intranasal challenge drug - Heroin Dependence
Phase 3CompletedNew York State Psychiatric Institute272009-05-012017-09-08
Buprenorphine for Prisoners
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP - Heroin Addiction
Phase 3CompletedFriends Research Institute, Inc.2132008-09-012018-08-29
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Directly Administered Antiretroviral Therapy (DAART), SAT - HIV Infections, Heroin Dependence
Phase 2 / Phase 3WithdrawnJohns Hopkins University2008-07-012015-04-15
ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
VIVITROL® 380 mg, Placebo - Opiate Dependence
Phase 3CompletedAlkermes, Inc.2502008-06-012017-02-10
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Vivitrol, memantine - Opioid Dependence, Heroin Dependence
Phase 2 / Phase 3CompletedNew York State Psychiatric Institute822008-06-012018-07-17
Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Buprenorphine - Opioid-Related Disorders, Heroin Dependence
Phase 2 / Phase 3CompletedNew York State Psychiatric Institute202007-12-012019-04-24
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
depot naltrexone, Oral Naltrexone - Opiate Dependence, Heroin Dependence
Phase 3CompletedNew York State Psychiatric Institute602007-09-012017-08-25
Addiction Treatment in Russia: Oral vs. Naltrexone Implant
naltrexone implant, oral naltrexone, oral placebo naltrexone - Heroin Dependence, Opioid-Related Disorders
Phase 2 / Phase 3CompletedUniversity of Pennsylvania3062006-07-012019-03-18
Directly Administered HIV Therapy in Methadone Clinics
Directly administered antiretroviral therapy (DAART) - HIV Infections, Heroin Dependence
Phase 2 / Phase 3CompletedJohns Hopkins University1072006-04-012015-04-15
Methadone Maintenance for Prisoners
Counseling Only, Counseling + Transfer, Counseling + Methadone - Heroin Addiction
Phase 3CompletedFriends Research Institute, Inc.2112003-09-012014-04-03
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
Buprenorphine/naloxone - Heroin Dependence, Morphine Dependence
Phase 3CompletedUniversity of California, Los Angeles1632001-02-012017-01-12
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
Buprenorphine/naloxone - Heroin Dependence, Morphine Dependence
Phase 3CompletedUniversity of California, Los Angeles3412001-01-012017-01-12
Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
Buprenorphine/naloxone - Heroin Dependence, Substance-Related Disorders
Phase 3CompletedNational Institute on Drug Abuse (NIDA)1996-04-012017-01-16
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
Buprenorphine - Heroin Dependence
Phase 3CompletedNational Institute on Drug Abuse (NIDA)2005-11-07

Narrower conditions

Opioid-Related Disorders (10)  ·  Amphetamine-Related Disorders (3)  ·  HIV Infections (2)  ·  Morphine Dependence (2)  ·  Substance Withdrawal Syndrome (2)  ·  Behavior, Addictive (1)  ·  Substance-Related Disorders (1)  ·  cyclopia sequence (1)

Broader conditions

Chemically-Induced Disorders (19)  ·  Mental Disorders (19)  ·  Narcotic-Related Disorders (19)  ·  Substance-Related Disorders (18)  ·  Opioid-Related Disorders (9)  ·  Blood-Borne Infections (2)  ·  Communicable Diseases (2)  ·  Genital Diseases (2)  ·  Immune System Diseases (2)  ·  Immunologic Deficiency Syndromes (2)  ·  Infections (2)  ·  Lentivirus Infections (2)  ·  RNA Virus Infections (2)  ·  Retroviridae Infections (2)  ·  Sexually Transmitted Diseases (2)

Interventions

Buprenorphine, Naloxone Drug Combination (5)  ·  Naltrexone (3)  ·  vivitrol (3)  ·  Buprenorphine (2)  ·  Counseling (1)  ·  Fluid Therapy (1)  ·  Heroin (1)  ·  Hydromorphone (1)  ·  Injections (1)  ·  Memantine (1)  ·  Methadone (1)  ·  Minocycline (1)  ·  Mirtazapine (1)  ·  Paliperidone Palmitate (1)  ·  Parturition (1)

Sponsors

New York State Psychiatric Institute (5)  ·  Universiti Sains Malaysia (3)  ·  Friends Research Institute, Inc. (2)  ·  Johns Hopkins University (2)  ·  National Institute on Drug Abuse (NIDA) (2)  ·  University of California, Los Angeles (2)  ·  Alkermes, Inc. (1)  ·  University of British Columbia (1)  ·  University of Pennsylvania (1)

Countries

United States (13)  ·  Malaysia (3)  ·  Russia (2)  ·  Canada (1)  ·  India (1)

Top investigators

Walter Ling, M.D. (3)  ·  Vicknasingam Kasinather, PhD (2)  ·  Adam Bisaga, MD (1)  ·  Alexander Okhapkin, Prof. (1)  ·  Alexander Sofronov, Prof. (1)  ·  Alexey Egorov, Prof. (1)  ·  Andrey Anipchenko, Dr. (1)  ·  Edvin Zvartau, Prof. (1)  ·  Edward Nunes, M.D. (1)  ·  Erik W Gunderson, M.D. (1)  ·  Eugenia Oveido-Joekes, Ph.D. (1)  ·  Evgeny Krupitsky, Prof. (1)  ·  George Woody, MD (1)  ·  Gregory M Lucas, MD,PhD (1)  ·  Gregory M. Lucas, MD, PhD (1)

Results publications

PMID 40342086, PMID 17628351, PMID 18612373, PMID 18855822, PMID 19339140, PMID 21529928, PMID 21715107, PMID 22882399, PMID 22945623, PMID 23036218, PMID 23701526, PMID 23874575, PMID 25580067, PMID 25619263, PMID 25901451, PMID 27049826, PMID 27436632, PMID 28526048, PMID 31787108

NIH funding

K23DA020000 (1), R01DA010746 (1), R01DA015822 (1), R01DA016237 (1), R01DA017317 (1), R01DA021579 (1)